about sade biotech

Established in 2015, and founded by a team of highly experienced life science executives, agri-tech experts and serial entrepreneurs, Sade is focused on realizing the promise of medical cannabis and personalized healthcare.

sade biotech

initially established to research, manage and develop science-backed and evidence-based medicinal cannabis products, Sadé Biotech initiated several pre-clinical and clinical studies. These studies were seeking unique formulations and chemical compositions to treat specific medical symptoms. The result of three years of research was ASAYA™, a real-time digital healthcare platform built upon human and machine learning to power better care for patients.
Sade Biotech also is developing a smart, connected medical device –a unique mechanism that enables to administer a precise, consistent dose of medical cannabis oil along with improving its stability and quality. Using Bluetooth technology and interconnected to a smartphone, the device will help monitor treatment and provide precision on both chemovar as well as dosage.

Cannabivar

Partnerships and investment in plant genetics mapping and analysis, and clinical research.

Group structure

CANNABIVAR

ISRAEL

plant genetics research

SadéBIOTECH

ISRAEL

BIG DATA PATIENT CARE PLATFORM

our Journey

The company was founded as a leading scientific research company and initially worked in conjunction with the ARO, Israel’s governmental Agriculture Research Organization, but has since expanded its activities to include genetic and scientific research and the development of big data AI solutions.

2015

Sade Ltd. is established and invested seed money in four Cannabis funded researches. All researches performed under Israel’s governmental institute of Agriculture Development: The ARO (Vulcani Center). Sade obtained its first Medical Cannabis permit to operate

2016

Two of the funded researches matured to commercial companies:

  • Plantext: Developed unique formulations for the treatment of Crohn’s & Colitis
  • Cannabivar: Identifying key genes that are responsible for metabolic pathways creating key chemical compounds in the Cannabis trichome
2017
  • Sade establishes European operations and raises funding towards the planning and construction of a state-of-the-art indoor facility.
  • Sade helps raise over $3.5M, mostly in Canada, to its daughter company, Plantext
2018
  • SADE closes a round of financing from Industry leaders, towards the development of SADE BIOTECH, its technology and science arm. Additional use of proceeds towards further cannabis genetics research
2019
  • Sade launches the development of ASAYA – a big data software platform to help healthcare providers and patients transform Medical Cannabis care
2020

Sade Biotech launches prototype of ASAYA big-data AI platform, including Healthcare Providers dashboard and Patients mobile app

Please join our ever-growing group of early adaptors. If you are a medical cannabis patient, user, healthcare provider, researcher or fan – and have information to share with the world: please click below, fill in brief info and join our journey.